Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Apnimed doses first patient in phase 2 trial of AD109 in obstructive sleep apnea

pharmaceutical-business-reviewNovember 27, 2020

Tag: AD109 , OSA , Apnimed

PharmaSources Customer Service